A randomized, open-label, two-period crossover study to evaluate the bioequivalence and food effect between two formulations of regorafenib in healthy adult participants
Authors
Cai‐Xia Yang (ORCID: https://orcid.org/0000-0002-6472-1929)
Xinghe Wang (ORCID: https://orcid.org/0000-0002-4197-8545)
Yan Li (ORCID: https://orcid.org/0000-0002-5921-7752)
Qi Lu (ORCID: https://orcid.org/0000-0002-7679-3567)
Na Zhao (ORCID: https://orcid.org/0000-0002-2249-4780)
A randomized, open-label, two-period crossover study to evaluate the bioequivalence and food effect between two formulations of regorafenib in healthy adult participants
Cai‐Xia Yang, Xinghe Wang, Yan Li, Qi Lu et al.
Local Database Links
1 links
Journal
Frontiers in Pharmacology
Topics
Colorectal Cancer Treatments and Studies
article
A randomized, open-label, two-period crossover study to evaluate the bioequivalence and food effect between two formulations of regorafenib in healthy adult participants
Cai‐Xia Yang, Xinghe Wang, Yan Li, Qi Lu, Na Zhao
article en
Abstract
No abstract available for this paper.
Publication Tag
Frontiers in PharmacologyVol. 16
Institutions
Capital Medical University (CN), Beijing Shijitan Hospital (CN)